The Recent Development of the Surgical Treatment for Hepatocellular Carcinoma

Abstract

The optimal treatment for hepatocellular carcinoma (HCC) should be selected based on tumor conditions, liver functional reserve, and performance status. Surgical treatment, such as liver resection and liver transplantation, is the most favorable treatment method; however, its indication criteria differ according to each country’s guidelines. In Western countries, liver resection is indicated only for early-stage HCC patients with Barcelona-Clinic Liver Cancer staging classification (BCLC) 0/A. While in Asian countries, liver resection is one of the treatment options for advanced HCC, such as BCLC B/C. Recently, the treatment of HCC is about to enter a drastic transitional period. It started with the widespread use of minimally invasive surgery for HCC, followed by a high rate of hepatitis C virus eradication with the advent of direct acting antivirals and developing a multidisciplinary treatment for highly advanced HCC. As a result, the importance of liver resection for HCC is increasing, and it is time to reconsider the criteria for selecting treatment methods for HCC patients. This article outlines current topics in the surgical treatment of HCC.

Synergy effects of copper ion in doxorubicin-based chelate prodrug for cancer chemo-chemodynamic combination therapy

“…Hepatocellular carcinoma (HCC) is the most common primary liver malignant tumor and a leading cause of cancer-related death worldwide (Mo et al., 2020 ; Mohamed et al., 2021 ). Despite the enormous achievement in cancer therapy during the past decades (Luerken et al., 2022 ; Llovet et al., 2021 ; Yang et al., 2021 ; Nakajima et al., 2021 ), chemotherapy is still the main therapeutic modality in the treatment of cancer (Oyama et al., 2021 ; Wang et al., 2021 ; Jin et al., 2021 ). As an anthracycline antibiotic, doxorubicin (DOX) is one of the most important chemotherapeutic agents that frequently used in multiple clinical protocols to treat many kinds of cancer, including HCC (Zheng et al., 2021 ; Zhou et al., 2022 ; Pho-Iam et al., 2021 ).…”

Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells

“…Hepatocellular carcinoma (HCC) is among the most common cancers occurring worldwide, and it has a poor prognosis owing to a high recurrence rate [ 1 ]. Most potentially curative therapies for HCC, such as surgical resection, transplantation, and ablation therapy, have limited efficacy in advanced stages, and metastatic recurrence or de novo development of HCC occurs in approximately 70% of these patients within 5 years [ 2 – 6 ]. Postoperative recurrence is the leading cause of death in these patients [ 7 , 8 ] which typically occurs within 2 years of resection [ 9 , 10 ].…”